Publications by authors named "F Montiel-Lopez"
Background: COPD due to biomass exposure (COPD-B) is highly prevalent in low- and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of fluticasone furoate/vilanterol (FF/V) 100/25 μg and umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnoea, health-related quality of life (HRQL), forced expiratory volume in 1 s (FEV) and inspiratory capacity (IC) during a period of 6 months in patients with COPD-B and COPD-C, at a third level referral centre in Mexico City.
View Article and Find Full Text PDFsRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variant.
Heliyon
April 2024
Article Synopsis
- The study investigates the relationship between certain genetic variants (rs2071288, rs3134940, rs184003, and rs2070600) and soluble-RAGE levels in patients with chronic obstructive pulmonary disease (COPD) related to biomass-burning smoke (BBS) and tobacco smoking.
- Researchers analyzed 2189 subjects divided into four groups to determine if these variants and RAGE levels were linked to COPD, but found no strong associations, except a marginal one for rs3134940 with COPD-BBS.
- The findings revealed that sRAGE plasma and sputum levels were lower in COPD patients compared to non-COPD individuals, with rs3134940 influencing these levels, but the genetic variants themselves did
Introduction: One of the major concerns with post-acute sequelae of COVID-19 (PASC) is the development of pulmonary fibrosis, for which no approved pharmacological treatment exists. Therefore, the primary aim of this open-label study was to evaluate the safety and the potential clinical efficacy of a prolonged-release pirfenidone formulation (PR-PFD) in patients having PASC-pulmonary fibrosis.
Methods: Patients with PASC-pulmonary fibrosis received PR-PFD 1800 mg/day (1200 mg in the morning after breakfast and 600 mg in the evening after dinner) for three months.
Clinical and microbiological characteristics and inflammatory profile during an exacerbation of COPD due to biomass exposure. A comparison with COPD due to tobacco exposure.
Respir Med
November 2022
Background: Patients with biomass exposure-related COPD (BE-COPD) is a prevalent disease in developing countries and requires a detailed study of its clinical and inflammatory characteristics, specifying interventions that may differ from tobacco exposure-related COPD (TE-COPD). The objective was to describe clinical characteristics, biomarkers of inflammation, T-helper cells, and microbiological agents during a COPD exacerbation in BE-COPD in comparison with TE-COPD.
Methods: A prospective observational study in patients with moderate or severe exacerbation was recruited either in the emergency room or the COPD clinic.